A British well known drug maker company called AstraZeneca on Thursday announced that its ovarian anemia and cancer medicines achieved their objectives in three different late stage trials. The positive outcomes give a jolt for the organization, which has lost a few licenses on its older and seasoned medications since 2012, wiping out the greater part of its deals. AstraZeneca stated Lynparza, the organization's cancer medications being mutually created with Merck and Co, enhanced reaction rates in patients with a type of backslid ovarian disease after the chemotherapy. The organization's anemia medication, Roxadustat, additionally met its fundamental objective in two separate examinations assessing its viability in enhancing hemoglobin count within the patients experiencing dialysis and the individuals who are most certainly not. AstraZeneca expressed its intends to examine consequences of the Lynparza contemplate with the U.S. Food and Drug Administration, which has officially affirmed Lynparza as a first-line support treatment for grown-ups with a type of ovarian cancer. Roxadustat, which AstraZeneca is creating along with FibroGen, was as of late endorsed in China before getting the green light by controllers in the United States and Europe, giving it a way to solidify its situation in a key market.